Free Trial

Enveric Biosciences (ENVB) 10K Form and Latest SEC Filings 2026

Enveric Biosciences logo
$1.97 -0.01 (-0.45%)
As of 03:34 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Enveric Biosciences SEC Filings & Recent Activity

Enveric Biosciences (NASDAQ:ENVB) has submitted 426+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 4 submitted on June 3, 2026.

Form 4
Enveric Biosciences, Inc. Reports Ownership Change on Jun. 3, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Enveric Biosciences Files Current Report on May. 15, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Enveric Biosciences Files Quarterly Report on May. 15, 2026

The 10-Q contains Enveric Biosciences's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Enveric Biosciences SEC Filing History

Browse Enveric Biosciences' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
06/03/2026 3:32 PM
Enveric Biosciences (890821) Issuer
Tucker Joseph Edward (1883914) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2026 3:34 PM
Coveney Kevin Michael (1967056) Reporting
Enveric Biosciences (890821) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/15/2026 3:15 PM
Enveric Biosciences (890821) Subject
Lind Global Fund III LP (2071860) Filed by
Form SCHEDULE 13G/A
05/15/2026 7:00 AM
Enveric Biosciences (890821) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/15/2026 7:05 AM
Enveric Biosciences (890821) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/04/2026 3:35 PM
Enveric Biosciences (890821) Filer
Form D
Notice of Exempt Offering of Securities 
04/29/2026 11:15 PM
Enveric Biosciences (890821) Filer
Form EFFECT
04/29/2026 4:27 PM
Enveric Biosciences (890821) Filer
Form 424B3
04/23/2026 3:30 PM
Enveric Biosciences (890821) Filer
Form S-3
Registration statement under Securities Act of 1933  
04/14/2026 3:05 PM
Enveric Biosciences (890821) Filer
Form DEF 14A
04/14/2026 3:06 PM
Enveric Biosciences (890821) Filer
Form DEFA14A
04/14/2026 3:07 PM
Enveric Biosciences (890821) Filer
Form ARS
04/03/2026 4:05 PM
Enveric Biosciences (890821) Filer
Form PRE 14A
03/27/2026 4:27 PM
Enveric Biosciences (890821) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/27/2026 4:25 PM
Enveric Biosciences (890821) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/17/2026 11:15 PM
Enveric Biosciences (890821) Filer
Form EFFECT
02/09/2026 8:28 PM
Enveric Biosciences (890821) Filer
Form S-1
Registration statement under Securities Act of 1933  
02/06/2026 3:45 PM
Enveric Biosciences (890821) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/06/2026 3:30 PM
Enveric Biosciences (890821) Filer
Form 424B5
02/04/2026 3:31 PM
Enveric Biosciences (890821) Subject
Lind Global Fund III LP (2071860) Filed by
Form SCHEDULE 13G
02/02/2026 7:29 PM
Enveric Biosciences (890821) Subject
INTRACOASTAL CAPITAL, LLC (1646799) Filed by
Form SCHEDULE 13G
01/28/2026 12:33 PM
Enveric Biosciences (890821) Filer
Form 424B5
01/09/2026 4:23 PM
Enveric Biosciences (890821) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/05/2026 11:39 AM
AdvisorShares Trust (1408970) Filed by
Enveric Biosciences (890821) Subject
Form SCHEDULE 13G/A
12/31/2025 3:15 PM
Enveric Biosciences (890821) Filer
Form 424B3
12/30/2025 11:15 PM
Enveric Biosciences (890821) Filer
Form EFFECT
12/30/2025 3:37 PM
Coveney Kevin Michael (1967056) Reporting
Enveric Biosciences (890821) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/30/2025 3:37 PM
Enveric Biosciences (890821) Issuer
WEBB MICHAEL D (1239463) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/30/2025 3:38 PM
Enveric Biosciences (890821) Issuer
Tucker Joseph Edward (1883914) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/30/2025 3:39 PM
Enveric Biosciences (890821) Issuer
Schabacker Marcus (1645282) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/30/2025 3:40 PM
Enveric Biosciences (890821) Issuer
PASQUALONE FRANK (1597334) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/30/2025 3:41 PM
Enveric Biosciences (890821) Issuer
Kegler George A. (1761753) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/30/2025 3:42 PM
DeWitt Sheila (2025032) Reporting
Enveric Biosciences (890821) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 4:06 PM
Enveric Biosciences (890821) Filer
Form D
Notice of Exempt Offering of Securities 
12/22/2025 3:17 PM
Enveric Biosciences (890821) Filer
Form S-3
Registration statement under Securities Act of 1933  
12/17/2025 7:20 PM
Enveric Biosciences (890821) Subject
INTRACOASTAL CAPITAL, LLC (1646799) Filed by
Form SCHEDULE 13G
12/12/2025 4:10 PM
Enveric Biosciences (890821) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/11/2025 11:41 AM
Enveric Biosciences (890821) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/10/2025 2:47 PM
Enveric Biosciences (890821) Subject
NORTHSTRIVE FUND II LP (2099270) Filed by
Form SCHEDULE 13G/A
12/10/2025 2:47 PM
Braeden Lichti (1982476) Filed by
Enveric Biosciences (890821) Subject
Form SCHEDULE 13G/A
12/09/2025 7:08 PM
Enveric Biosciences (890821) Filer
Form 424B3
Trump's New Dollar (Ad)

Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel

Watch the free briefing and see the three steps to prepare today
12/08/2025 11:15 PM
Enveric Biosciences (890821) Filer
Form EFFECT
12/05/2025 6:06 PM
Braeden Lichti (1982476) Filed by
Enveric Biosciences (890821) Subject
Form SCHEDULE 13G
12/05/2025 4:40 PM
Enveric Biosciences (890821) Subject
NORTHSTRIVE FUND II LP (2099270) Filed by
Form SCHEDULE 13G
12/05/2025 4:18 PM
Enveric Biosciences (890821) Filer
Form S-3/A
10/27/2025 3:30 PM
Enveric Biosciences (890821) Filer
Form DEF 14A
10/23/2025 3:30 PM
Enveric Biosciences (890821) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/10/2025 4:10 PM
Enveric Biosciences (890821) Filer
Form PRE 14A
10/03/2025 4:51 PM
AdvisorShares Trust (1408970) Filed by
Enveric Biosciences (890821) Subject
Form SCHEDULE 13G
10/03/2025 4:05 PM
Enveric Biosciences (890821) Filer
Form D
Notice of Exempt Offering of Securities 
09/29/2025 3:30 PM
Enveric Biosciences (890821) Filer
Form S-3
Registration statement under Securities Act of 1933  
09/24/2025 4:17 PM
Enveric Biosciences (890821) Subject
INTRACOASTAL CAPITAL, LLC (1646799) Filed by
Form SCHEDULE 13G
09/18/2025 3:30 PM
Enveric Biosciences (890821) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/02/2025 7:30 AM
Enveric Biosciences (890821) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/29/2025 4:10 PM
Enveric Biosciences (890821) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/29/2025 4:16 PM
Enveric Biosciences (890821) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/14/2025 3:08 PM
Enveric Biosciences (890821) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/14/2025 7:00 AM
Enveric Biosciences (890821) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Enveric Biosciences SEC Filings - Frequently Asked Questions

Enveric Biosciences (ENVB) has submitted 426+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Enveric Biosciences's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form 4 submitted on June 3, 2026. This was an insider ownership change filed by 4 - Enveric Biosciences, Inc. (0000890821) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:ENVB) was last updated on 6/4/2026 by MarketBeat.com Staff.
From Our Partners